Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty

Phase 3 Completed 72 enrolled AbbVie

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this extension study is to determine if leuprolide acetate (11.25 mg and 30 mg) is safe in treating children with Central Precocious Puberty over a longer period of time (36 months).

Timeline

Start: 2008-12
Primary completion: 2012-10
Completion: 2013-01

Publications

Lee PA, Klein K, Mauras N, Lev-Vaisler T, Bacher P. 36-month treatment experience of two doses of leuprolide acetate 3-month depot for children with central precocious puberty. J Clin Endocrinol Metab. 2014 Sep;99(9):3153-9. doi: 10.1210/jc.2013-4471. Epub 2014 Jun 13.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Leuprolide	Other / unclassified	11.25 mg	Intramuscular
Subject	Leuprolide	Other / unclassified	30 mg	Intramuscular

Safety Extension Study Of Leuprolide Acetate (Lupron Depot) In The Treatment Of Central Precocious Puberty

Summary

Timeline

Publications

Drugs

Indications